Accès direct au contenu


Version française > Programme

Programme & speakers

Day 1 - Tuesday 27th June 2017

08.45             Registration & welcome coffee
09.15 - 09.30  Welcome Address

09.30 - 11.00  Keynote Session I: ADCs, Empowering Cancer Therapy

Chairperson: Nicolas Joubert, Université de Tours

    
Antibody-Drug Conjugates for Cancer: Current Progress and Future Prospects.

Ravi Chari, Ph.D. - Vice President, Chemistry & Biochemistry, Distinguished Research fellow – Immunogen



Advancement in Antibody Drug Conjugates: A Step Closer to Magic Bullets in War against Cancer
• Advancement in ADCs unleashing a strong clinical pipeline of very promising anticancer drugs
• Five Rights of ADCs, meeting the challenges of off-target toxicities
• Translational approaches to ADC development

Rakesh Dixit, Ph.D., DABT - Vice President R & D, Global Head, Biologics Safety Assessment – MedImmune Inc.

11.00 - 11.30 Coffee Break and Poster Session - Partnering (B2B meetings)

11.30 - 12.15 Session II – part 1: Discovery of Novel ADCs Targets and Formats

Chairperson: Maxime Lampilas, Sanofi


Anthracycline-based ADCs :
Anthracycline-based antibody drug conjugates with potent immune-stimulatory functions

Roger Beerli, Ph.D. – Chief Scientific Officer – NBE Therapeutics


Sponsored presentation
Tissue Screen : the tissue based approach to target relevant protein
Renaud Burrer – R&D Manager -

12.15 - 13.30 Lunch and Poster Session - Partnering (B2B meetings)

13.30 - 15.00 Session II – part 2: Discovery of Novel ADCs Targets and Formats


An auristatin-based anti-HER3 ADC enhances the efficacy of radiation therapy in pancreatic cancer

Thierry Chardès, Pharm. D., Ph.D. - CNRS Research Director – Research Institute of Cancerology in Montpellier - LabEx MabImprove




Small is Beautiful – Humabody® Drug Conjugates, HDCs a Real Alternative to ADCs

Thomas Sandal - Vice President R&D – Crescendo Biologics




The two faces of interleukin-2; engineering towards applications in oncology and autoimmune diseases
Ekkehard Moessner, Ph.D. -
Head of Protein Engineering - Roche Innovation Center, Large Molecules Research


   

15.00 - 15.30 Coffee Break and Poster Session - Partnering (B2B meetings)

15.30 - 18.30 Pitch Session - New ADC Formats: Diagnostic and Immunomonitoring

Chairpersons: Andreas Pahl, Heidelberg Pharma - Saïd El Alaoui, Covalab

Pitch # 1 :
Gokhan YAHIOGLU – Antikor Biopharma

Not too big - Not too small : Fragment Drug Conjugates (FDCs) as alternatives to ADCS for solid tumors

Pitch # 2 :
Mathieu CINIER – Affilogic

Nanofitins as a versatile platform for cancer imaging and drug conjugates

Pitch # 3 :
Bruno TILLIER - Synthelis

Cell-free expression as an innovative tool for antigen production

Pitch # 4 :
Jonathan SJÖGREN – Genovis

The novel site specific ADC technology GlyCLICK preserves immunoreactivity and allows quantitative conjugation of functional groups to antibody Fc-glycans

Pitch # 5 :
David BONNAFOUS – McSAF

New linker technologies of ADC & bioconjugates developments

Pitch # 6 :
Jean VIALLET – Inovotion

INOVOTION Tests for drug discovery: Early identification of low value ADC
Pitch # 7 :
Thibault JONCKHEERE - ImmunXperts

Early Immunogenicity and Immunotoxicity Assessment and Risk Management for ADCs

Pitch # 8 :
Oreda BOUSSADIA – Epivax

The ISPRI Toolkit Rapidly Screens ADC Candidates for Immunogenic Potential Driven by T cell Epitope Content and Foreignness

Pitch # 9 :
Serge DESMOULINS – Agilent

Drug-to-antibody ratio determination for ADCs in serum enabled by a sample preparation platform that automates affinity purification and deglycosylation

Pitch # 10 :
Lisa RECNIK – ICRM-IBMM

Development of an Antibody Radiolabeled Drug Conjugate (ARDC) using 195mPt-Carboplatin for Theranostic Approach in Ovarian Cancer

Pitch # 11 :
Jean-Marc JOUMIER – EasyChelators

C-functionalized Cyclam derivatives as bifunctional chelating agent (BCA) analogues of TETA, TE2A and CB-TE2A

18.30       End of Day 1
20.00       Gala Dinner

Day 2 - Wednesday 28th June 2017

08.15          Registration & welcome coffee

08.30 - 10.30 Session III – Accelerate the Development of the Next-Generation ADCs

Chairperson: Alain Beck, Centre d'Immunologie Pierre Fabre


CovIsoLinkTM: New bacterial transglutaminase Q-tag substrate for the development of site specific Antibody Drug Conjugates

Saïd El Alaoui, Ph.D. – Chief Executive Officer - Covalab




Enzymatic site specific conjugation using transglutaminase to obtain homogeneous ADC

François Romagné, Ph.D. – Scientific Director – MI-mAbs


Amanitin-based Antibody-Drug-Conjugates as New Therapeutic Modalities for Cancer Therapy

Andreas Pahl, Prof. Dr. – Chief Scientific Officer – Heidelberg Pharma




Development of new cryptophycins as promising tubulin binder payloads for ADCs

Marie-Priscille Brun, Ph.D. – Immunoconjugate Leader / Chemical biology group – Sanofi

10.30 - 11.00 Coffee Break and Poster Session - Partnering (B2B meetings)

11.00 - 12.30 Session IV – Challenges in ADC developability, scale-up and manufacturing

Chairperson: François Romagné, MI-mAbs

Keynote presentation
Insights of multilevel state-of-the art analytical methods for ADCs structural assessment
Alain Beck, PhD - Senior Director, Analytical Chemistry, New Biological Entities - Centre d'Immunologie Pierre Fabre - Associate Editor of mAbs journal


Sponsored presentation
ADC Easy Access : From the Lab to the Clinic
Régis Lelou - Senior Bioengineer – R&D Chemicals



Sponsored presentation
Integrated services for immuno-conjugate development and production:

Symbiotic combination of R&D expertise and industrial leadership for successful development of mAbs
Eric Devic, Ph. D. – Founder-President and COO – GTP Technology



Novasep's integrated solutions for ADC
François D’Hooge, Ph.D.
- Head of Bioconjugation Unit – Novasep



Need for speed – how to accelerate the development of an ADC
Klaus Kaiser
- Head of Downstream – Bayer


12.30 - 14.00 Lunch and Poster Session - Partnering (B2B meetings)

14.00 - 16.00 Session V - Moving ADCs Forward Into the Clinic: Safety and Efficacy

Chairperson: François Lefoulon, Servier


Update on PBDs
Philip Howard, Ph.D. – CSO, Senior Fellow - Spirogen




Mechanisms of resistance to ADCs
Charles Dumontet, Prof. Ph.D
- Senior Physician in Hematology – Hospices civils de Lyon




Clinical pharmacology of ADCs
Gilles Paintaud, PU-PH – Head of CNRS UMR 7292 – University of Tours - LabEx MabImprove




ADC Safety & Toxicity: Technology Choices and Importance of Process Development to Control Safety related CQAs
Olivier Marcq, Ph.D.
– Group leader Development and Manufacturing – Agensys


16.00 - 17.00 Outsourcing roundtable: mAbs and ADCs outsourcing, opportunities and challenges - Partnering (B2B meetings)

Chairperson: Florence Lhospice, Innate Pharma

Arnaud Martin, Director CMO Business - Sanofi
Régis Lelou, Senior Bioengineer – R&D Chemicals - Lonza
Christophe Aussourd, Planning and Supply Director - Servier

17.00 - 17.30 Closing Remarks, Announcement of the AIS2018


17.30 End of Symposium


  • Facebook
  • twitter
  • google
  • imprimer
  • version PDF
  • Envoyer cette page

Retour au site institutionnel